Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recall by Genotype: Neuropeptide Stimulation
NCT05901467Phase 1Terminated
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kisspeptin 112-121 and gonadorelin in infertility. Primary endpoints: Endogenous Luteinizing Hormone Pulse Amplitude at 8 hours and Kisspeptin-induced Luteinizing Hormone Pulse Amplitude at 11 hours. Started Oct 2023; status: terminated.
02
Drugs
kisspeptin 112-121gonadorelin
03
Conditions
infertility
Beyond the preview
Go deeper on NCT05901467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901467.